What dose of ostarine did studies use?
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Healthy elderly men (over 60) and postmenopausal women (Dalton, 2011) | 0.1, 0.3, 1 or 3 mg daily, or placebo1 | 120 in all: 24 per group, 12 men and 12 women1 | 86 days1 |
| Cancer with weight loss (Dobs, NCT00467844) | 1 mg or 3 mg once daily by mouth, or placebo2 | 159 analysed for safety: men over 45 and postmenopausal women, at least 2% weight loss2 | Up to 113 days2 |
| Stage III or IV lung cancer before first-line chemotherapy, POWER design (Crawford, 2016) | 3 mg by mouth once a day, or placebo4 | 150 per arm planned; registries list 321 enrolled in the first POWER trial and 330 in the second456 | Up to 147 days4 |
| Postmenopausal women, stress incontinence (NCT03241342) | 1 mg or 3 mg once daily by mouth, or placebo7 | 491 enrolled7 | Primary outcome at 12 weeks7 |
| With a GLP-1 drug (NCT06282458) | 3 mg or 6 mg once daily by mouth, or placebo, each with semaglutide8 | 168 enrolled, aged 60 or over8 | Primary endpoint at 112 days, then enobosarm or placebo alone to day 1968 |
| Postmenopausal women, AR-positive, ER-positive, HER2-negative advanced breast cancer (Palmieri, 2024) | 9 mg or 18 mg daily by mouth, open-label3 | 136 randomised (n=72 on 9 mg, n=64 on 18 mg)3 | Primary endpoint at 24 weeks3 |
Trials of ostarine (enobosarm) gave 0.1, 0.3, 1 or 3 mg daily or placebo to 120 healthy elderly men and postmenopausal women for 86 days, 1 mg or 3 mg once daily or placebo for up to 113 days to 159 people with cancer, and 9 mg or 18 mg daily to 136 postmenopausal women with breast cancer, with the primary endpoint at 24 weeks; a DailyMed search found no ostarine label setting a dose.123
What trials gave, and for how long
The table is set at the top of the page
In the healthy elderly trial, lean body mass rose significantly against placebo only in the 3 mg arm (1,246.3 g against a placebo change of −73.2, also in grams, P < 0.001); the 1 mg arm changed by 588.7 g, which was not statistically significant (P = 0.055).1 Trial doses differ by condition: 1 mg or 3 mg in the cachexia and incontinence trials, 3 mg in the POWER trials, 3 mg or 6 mg with a GLP-1 drug, and 9 mg or 18 mg in breast cancer; none is a healthy-adult bodybuilding dose.24783
In the healthy elderly trial, women were assigned the same arms as men (12 of each group of 24), and the pack found no women-only dose beyond the postmenopausal women in the breast cancer (9 mg or 18 mg) and incontinence (1 mg or 3 mg) trials.137 Beyond daily dosing for each trial's length, the pack found no cycle or break schedule; an open-label phase 2 trial in AR-positive metastatic triple-negative breast cancer (Yuan, 2021), with 18 people enrolled, gave enobosarm 18 mg oral daily with pembrolizumab 200 mg intravenous (IV) every 3 weeks.9
Capsules, liquids and powders
Three trial registries list the study drug as softgel capsules: 3 mg once daily in the second POWER trial (NCT01355497), a total daily dose of 9 mg or 18 mg once daily in a breast cancer trial (NCT02463032), and 2 capsules once daily on the 1 mg or 3 mg arms of an incontinence trial (NCT03241342).6107
A 2017 JAMA analysis of 44 internet SARM products (Van Wagoner) found that only 23 (52%) contained any SARM, 25% held substances not on the label, 9% held no active substance, and 59% held amounts differing from the label.11 In that analysis, ostarine capsule products were labelled 10, 12, 12.5, 20 or 25 mg each and liquids 25 mg/mL or 50 mg/mL, with measured contents such as 1-10 mg in a capsule labelled 12 mg and 0.1-1 mg/mL in a liquid labelled 50 mg/mL.11
A research-chemical leaflet from Cayman Chemical, dated 08/06/2015, gives ostarine as dissolving in ethanol at about 25 mg/ml and in DMSO and DMF at about 15 mg/ml, and as sparingly soluble in aqueous buffers.12 It is marked for research only.12
Storage
For long-term storage, the same leaflet suggests keeping the crystalline solid as supplied at -20°C, with a listed stability of at least two years.12 The pack found no label storage or expiry and no stability data for any prepared liquid.
Frequently asked questions
Is ostarine approved?
How do you convert an ostarine dose in mg to mL?
The pack found no label or trial that gives ostarine volumes or syringe marks for a liquid. As maths only, a volume in mL is a dose in mg divided by a liquid's mg/mL, though measured contents of labelled liquids differed from their labels.11
Is ostarine combined with cardarine in any human trial?
The pack found no human trial of ostarine with cardarine.
References
- PMC. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. 2011. pmc.ncbi.nlm.nih.gov
- PMC. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. 2013. pmc.ncbi.nlm.nih.gov
- PubMed. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. 2024. pubmed.ncbi.nlm.nih.gov
- PMC. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 2016. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01355484: Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC). 2016. clinicaltrials.gov
- ClinicalTrials.gov. NCT01355497: Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. 2020. clinicaltrials.gov
- ClinicalTrials.gov. NCT03241342: Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence. 2020. clinicaltrials.gov
- ClinicalTrials.gov. NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt. 2025. clinicaltrials.gov
- PMC. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT02463032: Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer. 2020. clinicaltrials.gov
- PMC. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. pmc.ncbi.nlm.nih.gov
- Cayman Chemical. PRODUCT INFORMATION. cdn.caymanchem.com
- US FDA. Social Media Posts by Influencers and Online Sellers Promote SARMs Use. fda.gov
- US FDA. Dynamic Health Group dba SARMS AMERICA - 719257 - 12/12/2025. fda.gov